GABAPENTIN tablet

Land: Verenigde Staten

Taal: Engels

Bron: NLM (National Library of Medicine)

Koop het nu

Bijsluiter Bijsluiter (PIL)
31-01-2012
Productkenmerken Productkenmerken (SPC)
31-01-2012

Werkstoffen:

GABAPENTIN (UNII: 6CW7F3G59X) (GABAPENTIN - UNII:6CW7F3G59X)

Beschikbaar vanaf:

STAT Rx USA LLC

INN (Algemene Internationale Benaming):

GABAPENTIN

Samenstelling:

GABAPENTIN 600 mg

Toedieningsweg:

ORAL

Prescription-type:

PRESCRIPTION DRUG

therapeutische indicaties:

Gabapentin tablets USP are indicated for the management of postherpetic neuralgia in adults. Gabapentin tablets USP are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin tablets USP are also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 to 12 years. Gabapentin tablets USP are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. The abuse and dependence potential of gabapentin has not been evaluated in human studies.

Product samenvatting:

Gabapentin Tablets USP, 600 mg are available as white, oval shaped tablets, debossed “4443”, with a partial score on one side and “600” on the other side containing 600 mg gabapentin USP packaged in bottles of 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured In Israel By: TEVA PHARMACEUTICAL IND. LTD. Jerusalem, 91010, Israel Manufactured For: TEVA PHARMACEUTICALS USA Sellersville, PA 18960 Rev. J 8/2011

Autorisatie-status:

Abbreviated New Drug Application

Bijsluiter

                                STAT Rx USA LLC
----------
MEDICATION GUIDE
GABAPENTIN (GA-ba-PEN'-tin) TABLETS USP
Read the Medication Guide before you start taking gabapentin and each
time you get a refill. There may
be new information. This information does not take the place of
talking to your healthcare provider about
your medical condition or treatment.
What is the most important information I should know about gabapentin?
Do not stop taking gabapentin without first talking to your healthcare
provider.
Stopping gabapentin suddenly can cause serious problems.
Gabapentin can cause serious side effects including:
1.Like other antiepileptic drugs, gabapentin may cause suicidal
thoughts or actions in a very small
number of people, about 1 in 500.
Call a healthcare provider right away if you have any of these
symptoms, especially if they are new,
worse, or worry you:
•
thoughts about suicide or dying
•
attempts to commit suicide
•
new or worse depression
•
new or worse anxiety
•
feeling agitated or restless
•
panic attacks
•
trouble sleeping (insomnia)
•
new or worse irritability
•
acting aggressive, being angry, or violent
•
acting on dangerous impulses
•
an extreme increase in activity and talking (mania)
•
other unusual changes in behavior or mood
How can I watch for early symptoms of suicidal thoughts and actions?
•
Pay attention to any changes, especially sudden changes, in mood,
behaviors, thoughts, or
feelings.
•
Keep all follow-up visits with your healthcare provider as scheduled.
Call your healthcare provider between visits as needed, especially if
you are worried about symptoms.
Do not stop taking gabapentin without first talking to a healthcare
provider.
•
Stopping gabapentin suddenly can cause serious problems. Stopping a
seizure medicine suddenly
in a patient who has epilepsy can cause seizures that will not stop
(status epilepticus).
Suicidal thoughts or actions can be caused by things other than
medicines. If you have suicidal thoughts
or actions, your healthcare provider may check for other causes.

                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                GABAPENTIN - GABAPENTIN TABLET
STAT RX USA LLC
----------
GABAPENTIN TABLETS USP
RX ONLY
4443
4444
DESCRIPTION
Gabapentin tablets USP are an anticonvulsant for oral administration.
Gabapentin USP is described as 1-
(aminomethyl)cyclohexaneacetic acid. Gabapentin USP is a white to
off-white crystalline solid with a
pK of 3.7 and a pK of 10.7. It is freely soluble in water and both
basic and acidic aqueous solutions.
The log of the partition coefficient (n-octanol/0.05M phosphate
buffer) at pH 7.4 is -1.25. The
structural formula of gabapentin USP is:
C H NO M.W. 171.24
Each gabapentin tablet USP, for oral administration, contains 600 mg
or 800 mg of gabapentin USP and
contains the following inactive ingredients: lactose monohydrate,
microcrystalline cellulose and
polyethylene glycol.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
The mechanism by which gabapentin exerts its analgesic action is
unknown, but in animal models of
analgesia, gabapentin prevents allodynia (pain-related behavior in
response to a normally innocuous
stimulus) and hyperalgesia (exaggerated response to painful stimuli).
In particular, gabapentin prevents
pain-related responses in several models of neuropathic pain in rats
or mice (e.g., spinal nerve ligation
models, streptozocin-induced diabetes model, spinal cord injury model,
acute herpes zoster infection
model). Gabapentin also decreases pain-related responses after
peripheral inflammation (carrageenan
footpad test, late phase of formalin test). Gabapentin did not alter
immediate pain-related behaviors (rat
tail flick test, formalin footpad acute phase, acetic acid abdominal
constriction test, footpad heat
irradiation test). The relevance of these models to human pain is not
known.
The mechanism by which gabapentin exerts its anticonvulsant action is
unknown, but in animal test
systems designed to detect anticonvulsant activity, gabapentin
prevents seizures as do other marketed
anticonvulsants. Gabapentin exhibits antiseizure activity in mice and
rats in both the maximal
electroshock and penty
                                
                                Lees het volledige document
                                
                            

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten